← Back to Screener
Vivani Medical, Inc. Common Stock (DE) (VANI)
Price$1.31
Favorite Metrics
Price vs S&P 500 (26W)-21.38%
Price vs S&P 500 (4W)-8.39%
Market Capitalization$104.12M
All Metrics
Book Value / Share (Quarterly)$0.21
P/TBV (Annual)1.10x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.33
Price vs S&P 500 (YTD)-9.96%
Gross Margin (TTM)36.39%
Net Profit Margin (TTM)-993.79%
EPS (TTM)$-0.43
10-Day Avg Trading Volume0.14M
EPS Excl Extra (TTM)$-0.43
EPS (Annual)$-0.42
ROI (Annual)-130.61%
Gross Margin (Annual)36.39%
Net Profit Margin (5Y Avg)-583.18%
Cash / Share (Quarterly)$0.21
ROA (Last FY)-55.34%
EBITD / Share (TTM)$-0.42
ROE (5Y Avg)-151.99%
Operating Margin (TTM)-1004.73%
Cash Flow / Share (Annual)$-0.33
P/B Ratio6.62x
P/B Ratio (Quarterly)5.70x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-4.01x
ROA (TTM)-82.64%
EPS Incl Extra (Annual)$-0.42
Current Ratio (Annual)2.71x
Quick Ratio (Quarterly)2.56x
3-Month Avg Trading Volume0.28M
52-Week Price Return9.62%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.51
P/S Ratio (Annual)30.80x
Asset Turnover (Annual)0.20x
52-Week High$1.92
Operating Margin (5Y Avg)-586.01%
EPS Excl Extra (Annual)$-0.42
CapEx CAGR (5Y)28.87%
Tangible BV CAGR (5Y)41.24%
26-Week Price Return-17.39%
Quick Ratio (Annual)2.56x
13-Week Price Return-10.94%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.71x
Enterprise Value$87.885
Asset Turnover (TTM)0.12x
Book Value / Share Growth (5Y)-23.27%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)-0.97x
Pretax Margin (Annual)-993.79%
Cash / Share (Annual)$0.21
3-Month Return Std Dev66.93%
Gross Margin (5Y Avg)-2.08%
Net Income / Employee (TTM)$-1
ROE (Last FY)-130.61%
Net Interest Coverage (Annual)-0.06x
EPS Basic Excl Extra (Annual)$-0.42
Receivables Turnover (TTM)3.85x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.43
Receivables Turnover (Annual)7.04x
ROI (TTM)-317.03%
P/S Ratio (TTM)30.80x
Pretax Margin (5Y Avg)-583.18%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.87
Price vs S&P 500 (52W)-20.21%
Year-to-Date Return-7.32%
5-Day Price Return9.62%
EPS Normalized (Annual)$-0.42
ROA (5Y Avg)-96.95%
Net Profit Margin (Annual)-993.79%
Month-to-Date Return14.00%
Cash Flow / Share (TTM)$-0.55
EBITD / Share (Annual)$-0.41
Operating Margin (Annual)-1004.44%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-151.99%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.43
P/TBV (Quarterly)1.86x
P/B Ratio (Annual)5.70x
Inventory Turnover (TTM)-0.97x
Pretax Margin (TTM)-993.79%
Book Value / Share (Annual)$0.21
Price vs S&P 500 (13W)-11.63%
Beta2.30x
Revenue / Share (TTM)$0.00
ROE (TTM)-317.03%
52-Week Low$0.92
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.11
Industry Peers — Electromedical Equipment(29)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
VANIVivani Medical, Inc. Common Stock (DE) | 30.80x | — | 36.39% | -1004.73% | $1.31 |
MDTMedtronic plc | 3.13x | 3.01% | 65.16% | 17.00% | $85.65 |
MASIMasimo Corporation | 6.12x | 5.95% | 61.90% | 20.30% | $178.29 |
TMDXTransMedics Group, Inc. Common Stock | 6.58x | 88.21% | 59.92% | 17.93% | $109.12 |
LIVNLivaNova PLC Ordinary Shares | 2.56x | 8.24% | 68.04% | 14.09% | $65.01 |
ITGRInteger Holdings Corporation | 1.63x | 11.55% | 27.39% | 11.90% | $88.37 |
AXGNAxogen, Inc. Common Stock | 7.92x | 14.93% | 74.31% | -3.49% | $37.37 |
CNMDCONMED Corporation | 0.88x | 9.77% | 54.59% | 7.46% | $37.91 |
BLFSBioLife Solutions Inc. | 10.59x | 14.87% | 64.56% | -17.26% | $20.85 |
INMDInMode Ltd. Ordinary Shares | 2.45x | 12.45% | 78.54% | 23.05% | $14.33 |
CBLLCeriBell, Inc. Common Stock | 8.68x | — | 87.89% | -65.57% | $20.74 |
About
Vivani Medical is a clinical-stage biopharmaceutical company developing miniature subdermal implants using proprietary NanoPortal technology to deliver medications for chronic diseases with once or twice-yearly dosing. The platform addresses a critical market need by enabling long-term, consistent drug delivery to improve medication adherence. Its flagship candidates focus on GLP-1 delivery, competing in the rapidly growing metabolic disease market alongside established drugs like Ozempic and Wegovy.